Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

• by Shahram Salek-Ardakani

• June 2, 2026

Correction: Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report

• by Xiaofan Liao, Yuan Lu

• August 18, 2026

Association of the inflammatory marker suPAR with chronic pruritus of unknown origin – data from the SOMA.PRU study

• by Stefan M. Kahnert, Lara Jürgens, Leonie Dreher, Christian Schmidt-Lauber, Ansgar Koechel, Gina L. Frank, Tobias B. Huber, Meike Shedden-Mora, Sonja Ständer, Markus Ramm, Gudrun Schneider, Rupert Conrad

• June 16, 2026

FDA Approves Less Frequent Lebrikizumab Dosing

Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.

• by Kathryn Wighton

• June 10, 2026

• 2 min